Project Grant R01CA288236
Award Date
4/18/25
Completion Date
3/31/30
Dollars Obligated
$398K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Houston, TX 77204, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $158,020.00 in funding to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The key products and services to be delivered under this award include: Investigating persistence in response to PARP inhibitor treatment of BRCA1/2 mutant cancer cells to understand the mechanisms of mutagenic DNA repair,...
This federal Project Grant award, valued at $544,658.00 and provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), supports research at New York University School of Medicine to investigate the functional relevance of pyrimidine sensing and response pathways in tumor metabolism and cancer therapy. The key objectives of this 5-year research project are to: 1) understand how pyrimidine overflow and disruption of the p53-dependent ribosome biogenesis checkpoint...
This National Cancer Institute (NCI) Project Grant award under the Cancer Treatment Research program (CFDA 93.395) provides $680,507 to The Regents of the University of California, San Francisco (UCSF) to elucidate mechanisms of cancer cell persistence and identify druggable targets to eliminate persister cells in KRAS-mutant non-small cell lung cancer. The 5-year project aims to: 1) illuminate signals that promote persistence in relevant biological contexts, 2) identify and validate targets...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding for research aimed at understanding the metabolic crosstalk mechanisms that contribute to treatment resistance in pancreatic ductal adenocarcinoma (PDA). The award totaling $1,273,648 will support a 5-year project at the University of California, Irvine to investigate how PDA tumor cells develop metabolic adaptations, particularly related to asparagine production, that confer...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $530,122 to Cold Spring Harbor Laboratory to conduct research aimed at understanding the complex interactions between tumors and the host organism. The overarching goal is to elucidate the mechanistic explanation for the observation that a ketogenic diet delays tumor growth but accelerates cancer cachexia and shortens survival in two IL-6 associated murine cancer models. The research will...
This $544,478 five-year Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The University of Texas Southwestern Medical Center will support research to investigate the mechanisms by which cancer cells maintain and regulate their purine nucleotide pools through the de novo and salvage synthesis pathways. The research aims to provide critical insights into purine nucleotide metabolism in cancer, with the goal of identifying strategies to effectively...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $122,346 to the University of Colorado to conduct research aimed at defining the transition from deep cellular quiescence to permanent cell senescence. The research will use time-lapse microscopy and RNA sequencing to elucidate the molecular mechanisms underlying the relationship between quiescence and senescence, with the goal of improving chemotherapy treatments and identifying...
This federal Project Grant award, valued at $160,330.00 and awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), aims to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The key products or services to be delivered under this award are: Generation of organoid models by introducing oncogenic mutations into primary human lung stem and progenitor cell populations...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $682,596 in funding to The University of Texas Southwestern Medical Center to conduct research on the metabolic mechanisms driving glioma (a type of brain cancer) progression. The research aims to: 1) dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas, 2) determine the impact of these metabolic alterations on tumor...
This $424,836 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Texas MD Anderson Cancer Center to investigate and eliminate drug-tolerant persister cells in small cell lung cancer (SCLC). The key products and services to be delivered under this 5-year award include: Molecular characterization of SCLC drug-tolerant persister cells in preclinical models and patient samples to track their emergence and...